Analysis

4 Key Takeaways As HHS Demands Drug Prices In TV Ads

Law360 (October 15, 2018, 4:33 PM EDT) -- The U.S. Department of Health and Human Services on Monday aired its eagerly awaited plan to force disclosure of drug prices in pharmaceutical advertisements, setting the stage for a major court fight.

Here are four key takeaways about the plan’s details, possible impact and likely prospects in litigation.

How Price Disclosures Would Work

The department fleshed out its plan in a 45-page proposed rule that was touted in a speech by HHS Secretary Alex Azar. The rule, which quickly drew veiled threats of litigation, has been expected for several months and is part of the Trump administration’s wide-ranging campaign to ease...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS